Statin Therapy in Stroke Prevention and Management

Primary Prevention of Stroke

The American Heart Association recommends statins for primary prevention in patients with multiple risk factors for coronary heart disease, with a reduction in stroke risk of approximately 21% in patients at risk for cardiovascular disease, with stroke risk decreasing 15.6% for each 10% reduction in serum LDL cholesterol 3, 4
Each 1 mmol/L (39 mg/dL) decrease in LDL cholesterol is associated with a 21.1% reduction in stroke risk, according to the American College of Cardiology 5
In patients with an estimated 5-year risk of major vascular events <10%, every 39-mg/dL reduction in LDL results in a 24% reduction in stroke risk, similar to higher-risk categories, as stated by the American Stroke Association 6

High-dose statin therapy is strongly indicated for all patients with ischemic stroke or TIA to reduce the risk of recurrent stroke and major cardiovascular events, with a 16% reduction in the risk of recurrent stroke and a 20% reduction in major cardiovascular events, according to the American Heart Association 1, 2
The American College of Cardiology recommends high-dose statin therapy for patients with ischemic stroke or TIA presumed to be due to atherosclerosis, to reduce the risk of recurrent stroke and cardiovascular events (Class IIa-B) 10
Among patients with carotid stenosis, statin therapy was associated with a 33% reduction in the risk of any stroke and a 43% reduction in risk of major coronary events, as reported by the American Heart Association 4, 7

The beneficial effect of statins on ischemic stroke is primarily related to their capacity to reduce progression or induce regression of atherosclerosis, according to the American College of Cardiology 5
Statin therapy slows the progression of carotid intima-media thickness (IMT), with the magnitude of LDL cholesterol reduction correlating inversely with the progression, as stated by the American Heart Association 4

More intensive statin therapy that achieves an LDL cholesterol of 55 to 80 mg/dL results in a lower risk of stroke than less intensive therapy that achieves an LDL cholesterol of 81 to 135 mg/dL, according to the American Stroke Association 6
Higher versus lower statin doses show a significant reduction in the composite of fatal and nonfatal strokes (RR 0.86; 95% CI: 0.77–0.96), as reported by the American College of Cardiology 5

Meta-analyses have found no significant overall increase in the incidence of hemorrhagic stroke with statin therapy (OR 1.08; 95% CI: 0.88–1.32), according to the International Journal of Stroke 6, 5
However, in secondary prevention trials in patients with a past history of stroke, statin assignment was associated with an increased risk of hemorrhagic stroke (RR 1.73; 95% CI: 1.19–2.50), as reported by the International Journal of Stroke 8, 9

For patients with prior intracerebral hemorrhage, especially lobar ICH, the risk-benefit ratio of statin therapy should be carefully evaluated, according to the American College of Cardiology 2

For primary prevention, the American Heart Association recommends assessing cardiovascular risk factors and initiating statin therapy in patients with multiple risk factors for coronary heart disease, with a target LDL-C reduction based on risk category 6
For secondary prevention after ischemic stroke or TIA, the American College of Cardiology recommends starting high-dose statin therapy (atorvastatin 80 mg daily) in patients with ischemic stroke or TIA, with a target LDL-C <70 mg/dL for patients with atherosclerotic disease 2